Navigation Links
Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results
Date:5/14/2009

se of CPP-109 for the treatment of cocaine addiction by the end of the second quarter of 2009. Assuming positive data, we will likely seek to meet with the FDA and begin designing the Phase III 'pivotal' cocaine trial during the second half of 2009 that we believe will be required in order to meet our ultimate goal of filing an NDA for CPP-109. In addition, we also expect to have the top-line results of our 57-patient proof-of-concept study evaluating the use of CPP-109 in the treatment of methamphetamine addiction during the third quarter of 2009. Furthermore, we believe that our strengthened balance sheet will enable us to engage prospective corporate partners and explore a variety of potential transactions on terms that may prove to be favorable to our stockholders."

"Additionally, we are actively exploring opportunities to obtain government funding from agencies that operate under the National Institutes of Health umbrella to further our development plans, which include developing large-scale clinical trials using CPP-109 to treat cocaine and methamphetamine addiction, as well as pilot studies for other addictions including alcohol and nicotine dependence."

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive-compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders . Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
4. Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
5. CATalyst Summit Declared a Success: Its All About the Cat!
6. Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the Investment in Innovation (In3) West Conference on February 29, 2008 in Las Vegas, NV
7. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
8. Case in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution
9. Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
10. Congress Approves ePrescribing Initiative in Medicare Reform Bill: Critical Catalyst in Driving a New Generation of Prescribing
11. CATalyst Council Forms to Address Feline Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... mothers are less likely than white moms to breast-feed ... in neighborhoods with many black residents do less to ... residents, a U.S. government study finds. Key practices ... centers where the black population is higher than average, ... Prevention reported Thursday. These practices include efforts to ...
(Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- Among seniors, ... suggests. The study involved more than 2,500 people, aged ... the study and again two, six and eight years later. ... in the person,s risk of death during the study period, ... and effect, researchers led by Sharon Christ of Purdue University ...
(Date:8/21/2014)... York, New York (PRWEB) August 21, 2014 ... filed against C.R. Bard, Inc. continue to move ... U.S. District Court, Southern District of West Virginia, ... Order issued on August 14th, the Court has ... evidence that requires special handling, division, storage and ...
(Date:8/21/2014)... to focus on her body in terms of how ... as a complete human being with thoughts and feelings. ... the media, how does it affect individual romantic relationships? ... , a SAGE journal, finds that more objectification of ... of sexual pressure and coercion., Researchers Laura R. Ramsey ...
(Date:8/21/2014)... FL (PRWEB) August 21, 2014 The ... published today in The Journal of the American Medical ... more invasive cancers and reduces unnecessary recalls. Memorial Healthcare ... in the study. , “This study confirms what we ... invasive, harmful cancers we want to find and, at ...
Breaking Medicine News(10 mins):Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2
... protein involved in Huntingtons disease take place earlier in ... College of Medicine in Houston in a report that ... , This research provides evidence of toxicity by huntingtin ... disease process, said Dr. Juan Botas, associate professor of ...
... As Americans increasingly seek a quick fix to physical ... crossfire of a debate about the potential benefits and ... A panel discussion entitled, The Uses of Medications in ... led by internationally renowned psychoanalyst Glen O. Gabbard, M.D., ...
... Department of Energy,s Brookhaven National Laboratory have found new ... while others don,t. Examining how the human brain responds ... various stages of fullness, the scientists have identified brain ... target these circuits may prove useful in controlling chronic ...
... Metabothin B56 with Ephedra Extract Released Just in Time for the Holiday ... ... CITY, Jan. 9 The average American gains 50%,of his yearly weight ... Americans that are already overweight., Metabothin ( http://www.metabothin.net ), the herbal ...
... can reduce healthcare costs by aiding in senior health and ... ... DSS Research, a,leader in market research for the health insurance industry, ... (SrHRA(TM)) for the 65 and over population. SrHRA provides,proven health risk stratification ...
... Bangladesh, Kenya, Tanzania and ... ... announced that it has,entered into four new technology transfers with local ... therapy are needed. These companies are Regal,Pharmaceuticals in Kenya, CAPS Holdings ...
Cached Medicine News:Health News:Uses of medications in psychoanalysis 2Health News:Overweight people may not know when they've had enough 2Health News:Overweight people may not know when they've had enough 3Health News:Metabothin B56 with Ephedra Extract Now Available 2Health News:DSS Research Announces Senior Health Risk Assessment Tool 2Health News:Roche Engages in Four Additional AIDS Technology Transfers to Strengthen Local Manufacturing in World's Poorest Countries 2Health News:Roche Engages in Four Additional AIDS Technology Transfers to Strengthen Local Manufacturing in World's Poorest Countries 3Health News:Roche Engages in Four Additional AIDS Technology Transfers to Strengthen Local Manufacturing in World's Poorest Countries 4
(Date:8/21/2014)... CYBX ) today announced results for the quarter ended ... Operating results for the first quarter of fiscal ... other achievements, include: , Worldwide net product sales of ... net sales of $13.2 million, an increase of 14.5% on ... reached a new high of $58.8 million, an increase of ...
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium Pharmaceuticals, ... specialty biopharmaceutical company, today announced positive results from ... clostridium histolyticum (or CCH) for the treatment of ... In the Phase 2a trial, all three doses ... (0.84mg)) showed an improvement in the appearance of ...
(Date:8/20/2014)...  The National Association of Drug Diversion Investigators ... the real-time, pseudoephedrine (PSE) blocking system in Kentucky. The ... (NPLEx), automatically blocks unlawful PSE sales and helps ... make arrests. Data released by NPLEx shows electronic ... the sale of more than 23,478 boxes of medicine ...
Breaking Medicine Technology:Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA ), ... its preliminary unaudited sales range for the fourth quarter and ... discuss these preliminary sales will be held on January 6, ... at 9:00 pm China Standard Time). The Company will issue ...
... WebMD Health Corp. (Nasdaq: WBMD ) today announced ... due 2018 in a private placement. WebMD also expects to ... to purchase up to an additional $50 million aggregate principal ... qualified institutional buyers pursuant to Rule 144A under the Securities ...
Cached Medicine Technology:Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range 2Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range 3WebMD Announces Proposed Offering of Convertible Notes 2
BioSoft alcohol gel hand antiseptic with soothing moisturizers is a fast-acting, broad-spectrum antimicrobial solution. BioSoft alcohol gel hand antiseptic applies easily, requires no rinsing and dri...
... Scrub Care povidone-iodine (PVP-I) antimicrobial solutions ... control in all hospital and health-care settings. ... gel have a broad spectrum of activity, ... bacteria that may cause infection. The new ...
... hand sanitizers like Aplicare No Rinse Isopropyl ... as the recommended product for hand disinfection ... Guidelines for hand hygiene., According to the ... be prevented with better infection control programs. ...
This is long known for its purity and mildness, Castile Soap is also an effective cleaning agent that is used in a variety of applications. It rinses clean while leaving the skin soft and healthy....
Medicine Products: